The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical CDMO Solution Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Active Pharmaceutical Ingredient (API) Manufacturing
1.2.3 Finished Dosage Formulation (FDF) Development and Manufacturing
1.2.4 Secondary Packaging
1.2.5 Others
1.3 Market by Application
1.3.1 Global Pharmaceutical CDMO Solution Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CDMO Solution Market Perspective (2018-2029)
2.2 Pharmaceutical CDMO Solution Growth Trends by Region
2.2.1 Global Pharmaceutical CDMO Solution Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pharmaceutical CDMO Solution Historic Market Size by Region (2018-2023)
2.2.3 Pharmaceutical CDMO Solution Forecasted Market Size by Region (2024-2029)
2.3 Pharmaceutical CDMO Solution Market Dynamics
2.3.1 Pharmaceutical CDMO Solution Industry Trends
2.3.2 Pharmaceutical CDMO Solution Market Drivers
2.3.3 Pharmaceutical CDMO Solution Market Challenges
2.3.4 Pharmaceutical CDMO Solution Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CDMO Solution Players by Revenue
3.1.1 Global Top Pharmaceutical CDMO Solution Players by Revenue (2018-2023)
3.1.2 Global Pharmaceutical CDMO Solution Revenue Market Share by Players (2018-2023)
3.2 Global Pharmaceutical CDMO Solution Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceutical CDMO Solution Revenue
3.4 Global Pharmaceutical CDMO Solution Market Concentration Ratio
3.4.1 Global Pharmaceutical CDMO Solution Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO Solution Revenue in 2022
3.5 Pharmaceutical CDMO Solution Key Players Head office and Area Served
3.6 Key Players Pharmaceutical CDMO Solution Product Solution and Service
3.7 Date of Enter into Pharmaceutical CDMO Solution Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CDMO Solution Breakdown Data by Type
4.1 Global Pharmaceutical CDMO Solution Historic Market Size by Type (2018-2023)
4.2 Global Pharmaceutical CDMO Solution Forecasted Market Size by Type (2024-2029)
5 Pharmaceutical CDMO Solution Breakdown Data by Application
5.1 Global Pharmaceutical CDMO Solution Historic Market Size by Application (2018-2023)
5.2 Global Pharmaceutical CDMO Solution Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pharmaceutical CDMO Solution Market Size (2018-2029)
6.2 North America Pharmaceutical CDMO Solution Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pharmaceutical CDMO Solution Market Size by Country (2018-2023)
6.4 North America Pharmaceutical CDMO Solution Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CDMO Solution Market Size (2018-2029)
7.2 Europe Pharmaceutical CDMO Solution Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pharmaceutical CDMO Solution Market Size by Country (2018-2023)
7.4 Europe Pharmaceutical CDMO Solution Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CDMO Solution Market Size (2018-2029)
8.2 Asia-Pacific Pharmaceutical CDMO Solution Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pharmaceutical CDMO Solution Market Size by Region (2018-2023)
8.4 Asia-Pacific Pharmaceutical CDMO Solution Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CDMO Solution Market Size (2018-2029)
9.2 Latin America Pharmaceutical CDMO Solution Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pharmaceutical CDMO Solution Market Size by Country (2018-2023)
9.4 Latin America Pharmaceutical CDMO Solution Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CDMO Solution Market Size (2018-2029)
10.2 Middle East & Africa Pharmaceutical CDMO Solution Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pharmaceutical CDMO Solution Market Size by Country (2018-2023)
10.4 Middle East & Africa Pharmaceutical CDMO Solution Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recipharm AB
11.1.1 Recipharm AB Company Detail
11.1.2 Recipharm AB Business Overview
11.1.3 Recipharm AB Pharmaceutical CDMO Solution Introduction
11.1.4 Recipharm AB Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.1.5 Recipharm AB Recent Development
11.2 Lonza Group
11.2.1 Lonza Group Company Detail
11.2.2 Lonza Group Business Overview
11.2.3 Lonza Group Pharmaceutical CDMO Solution Introduction
11.2.4 Lonza Group Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.2.5 Lonza Group Recent Development
11.3 Catalent
11.3.1 Catalent Company Detail
11.3.2 Catalent Business Overview
11.3.3 Catalent Pharmaceutical CDMO Solution Introduction
11.3.4 Catalent Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.3.5 Catalent Recent Development
11.4 Patheon (Thermo Fisher Scientific)
11.4.1 Patheon (Thermo Fisher Scientific) Company Detail
11.4.2 Patheon (Thermo Fisher Scientific) Business Overview
11.4.3 Patheon (Thermo Fisher Scientific) Pharmaceutical CDMO Solution Introduction
11.4.4 Patheon (Thermo Fisher Scientific) Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.4.5 Patheon (Thermo Fisher Scientific) Recent Development
11.5 Siegfried AG
11.5.1 Siegfried AG Company Detail
11.5.2 Siegfried AG Business Overview
11.5.3 Siegfried AG Pharmaceutical CDMO Solution Introduction
11.5.4 Siegfried AG Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.5.5 Siegfried AG Recent Development
11.6 SGS Quay Pharmaceuticals
11.6.1 SGS Quay Pharmaceuticals Company Detail
11.6.2 SGS Quay Pharmaceuticals Business Overview
11.6.3 SGS Quay Pharmaceuticals Pharmaceutical CDMO Solution Introduction
11.6.4 SGS Quay Pharmaceuticals Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.6.5 SGS Quay Pharmaceuticals Recent Development
11.7 Curia
11.7.1 Curia Company Detail
11.7.2 Curia Business Overview
11.7.3 Curia Pharmaceutical CDMO Solution Introduction
11.7.4 Curia Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.7.5 Curia Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Pharmaceutical CDMO Solution Introduction
11.8.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Samsung Biologics
11.9.1 Samsung Biologics Company Detail
11.9.2 Samsung Biologics Business Overview
11.9.3 Samsung Biologics Pharmaceutical CDMO Solution Introduction
11.9.4 Samsung Biologics Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.9.5 Samsung Biologics Recent Development
11.10 Fujifilm Diosynth Biotechnologies
11.10.1 Fujifilm Diosynth Biotechnologies Company Detail
11.10.2 Fujifilm Diosynth Biotechnologies Business Overview
11.10.3 Fujifilm Diosynth Biotechnologies Pharmaceutical CDMO Solution Introduction
11.10.4 Fujifilm Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.10.5 Fujifilm Diosynth Biotechnologies Recent Development
11.11 Societal CDMO
11.11.1 Societal CDMO Company Detail
11.11.2 Societal CDMO Business Overview
11.11.3 Societal CDMO Pharmaceutical CDMO Solution Introduction
11.11.4 Societal CDMO Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.11.5 Societal CDMO Recent Development
11.12 Aenova Group
11.12.1 Aenova Group Company Detail
11.12.2 Aenova Group Business Overview
11.12.3 Aenova Group Pharmaceutical CDMO Solution Introduction
11.12.4 Aenova Group Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.12.5 Aenova Group Recent Development
11.13 Eurofins CDMO
11.13.1 Eurofins CDMO Company Detail
11.13.2 Eurofins CDMO Business Overview
11.13.3 Eurofins CDMO Pharmaceutical CDMO Solution Introduction
11.13.4 Eurofins CDMO Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.13.5 Eurofins CDMO Recent Development
11.14 Piramal Group
11.14.1 Piramal Group Company Detail
11.14.2 Piramal Group Business Overview
11.14.3 Piramal Group Pharmaceutical CDMO Solution Introduction
11.14.4 Piramal Group Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.14.5 Piramal Group Recent Development
11.15 WuXi AppTec Group
11.15.1 WuXi AppTec Group Company Detail
11.15.2 WuXi AppTec Group Business Overview
11.15.3 WuXi AppTec Group Pharmaceutical CDMO Solution Introduction
11.15.4 WuXi AppTec Group Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.15.5 WuXi AppTec Group Recent Development
11.16 Fareva
11.16.1 Fareva Company Detail
11.16.2 Fareva Business Overview
11.16.3 Fareva Pharmaceutical CDMO Solution Introduction
11.16.4 Fareva Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.16.5 Fareva Recent Development
11.17 Strides Pharma Science
11.17.1 Strides Pharma Science Company Detail
11.17.2 Strides Pharma Science Business Overview
11.17.3 Strides Pharma Science Pharmaceutical CDMO Solution Introduction
11.17.4 Strides Pharma Science Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.17.5 Strides Pharma Science Recent Development
11.18 Famar Health Care Service
11.18.1 Famar Health Care Service Company Detail
11.18.2 Famar Health Care Service Business Overview
11.18.3 Famar Health Care Service Pharmaceutical CDMO Solution Introduction
11.18.4 Famar Health Care Service Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.18.5 Famar Health Care Service Recent Development
11.19 WuXi Biologics
11.19.1 WuXi Biologics Company Detail
11.19.2 WuXi Biologics Business Overview
11.19.3 WuXi Biologics Pharmaceutical CDMO Solution Introduction
11.19.4 WuXi Biologics Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.19.5 WuXi Biologics Recent Development
11.20 Asymchem
11.20.1 Asymchem Company Detail
11.20.2 Asymchem Business Overview
11.20.3 Asymchem Pharmaceutical CDMO Solution Introduction
11.20.4 Asymchem Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.20.5 Asymchem Recent Development
11.21 Pfizer CentreOne
11.21.1 Pfizer CentreOne Company Detail
11.21.2 Pfizer CentreOne Business Overview
11.21.3 Pfizer CentreOne Pharmaceutical CDMO Solution Introduction
11.21.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO Solution Business (2018-2023)
11.21.5 Pfizer CentreOne Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details